PET Imaging Agent for Glioma Approved by FDA
KEY TAKEAWAYS
- The FDA approved Pixclara as the first PET imaging agent for glioma.
- The agent is indicated to help distinguish recurrent or progressive glioma from treatment-related change when used with other diagnostic evaluations.
- The approval applies to adults and children aged 1 month and older.
The Food and Drug Administration (FDA) approved Pixclara (floretyrosine F 18; Telix Pharmaceuticals, Melbourne, Australia; Indianapolis, IN) as the first PET imaging agent for glioma, according to a statement from the National Brain Tumor Society.
Pixclara is approved for use with other diagnostic evaluations to help differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients aged 1 month and older. The approval gives clinicians another tool for evaluating unclear posttreatment scans, particularly when it is difficult to tell whether glioma is progressing or imaging changes are treatment related.
After glioma treatment, contrast-enhanced magnetic resonance imaging (MRI) may show findings that raise concern for progression. In some cases, however, those findings may reflect treatment-related effects, including radiation necrosis or pseudoprogression. Pixclara is an amino acid PET imaging agent designed to provide additional information that can be considered alongside MRI and other clinical assessments.
Practical Implications in the Clinic
For neurologists, neuro-oncologists, and multidisciplinary brain tumor teams, the approval provides a new imaging option when conventional imaging leaves uncertainty about whether glioma has recurred or progressed. The indication specifies that Pixclara should be used in conjunction with other diagnostic evaluations, rather than as a standalone test.
The availability of fluorine-18–based PET imaging may also be relevant for clinical adoption, because fluorine-18 tracers can generally be distributed to PET-capable centers from regional radiopharmacies. This may support broader access compared with imaging agents that require on-site cyclotron production.
The approval does not replace MRI as a central component of glioma monitoring. Instead, Pixclara may be used as a complementary imaging tool in cases where additional information could help inform treatment planning, surveillance decisions, or discussions with patients and families about uncertain posttreatment imaging findings.
Source
National Brain Tumor Society. FDA approves first PET imaging agent for glioma. Published September 14, 2026. Accessed September 22, 2026. https://braintumor.org/news/fda-approves-first-pet-imaging-agent-for-glioma/?fbclid=IwcGRvZgVmZGlkFlDo6TUJMDakl_K97x9Cson2iw_j7X1leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEec1NRqz1Qnbn1vEQP6IOaMbAHKoloiUUCg3TtouC0ROVnSWIo3rVuAtfXab0_aem_rQuAjbiWRApxkXRL6-0-aA